TECH Earnings Prediction
The chart below shows how TECH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TECH sees a +1.97% change in stock price 10 days leading up to the earnings, and a +1.49% change 10 days following the report. On the earnings day itself, the stock moves by +2.66%. This data can give you a slight idea of what to expect for the next quarter's release.
TECH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
272.60M
0.37%
-1.57%
Gross Margin
64.78%
-4.06%
-3.13%
Operating Margin
18.04%
-19.03%
-9.98%
Net Margin
10.08%
-45.25%
-45.25%
EPS
0.17
-45.16%
-45.16%
No Data Available
TECH Earnings Analysis
Bio-Techne Corp Corporation (TECH.O) Earnings Conference Call
Positive
Quarterly Organic Revenue Growth: 9% organic revenue growth for the quarter, driven by strong performance in biopharma end markets and traction in ExosomeDx and Spatial Biology franchises.
Operating Margin Improvement: Adjusted operating margin increased 110 basis points sequentially to 30.1%, indicating ongoing improvement in operating efficiency and profitability.
GMP Reagents Revenue Surge: GMP reagents revenue increased over 90% in Q2, with a trailing twelve month revenue growth of just over 40% organically, reflecting strong demand from cell therapy customers.
Protein Segment Revenue Growth: Protein analysis segment delivered 8% organic revenue growth, marking the best performance since the pandemic-related headwinds began, with strong sales momentum in automated workflow solutions.
Diagnostics Segment Growth: Diagnostics and Spatial Biology segment achieved 12% organic growth in Q2, supported by the successful launch of the COMET system and increased adoption of precision diagnostic tools.
Negative
China Sales Decline: Sales in China declined low single digits, indicating ongoing challenges in the economic environment and a lack of growth in a key market.
SG&A Expense Increase: Adjusted SG&A expenses increased to 32% of revenue from 31.2% in the prior year, reflecting higher costs associated with reinstated incentive compensation.
Diagnostics Segment Profitability Decline: Operating margin for the Diagnostics and Spatial Biology segment decreased to 3.9%, down from 6% in the prior year, highlighting profitability challenges in this area.
Foreign Exchange Impact on Revenue: The company anticipates a headwind of approximately 1% of sales in the back half of the fiscal year due to foreign exchange fluctuations, negatively impacting revenue growth.
Q3 Organic Growth Outlook: The organic growth outlook for Q3 is expected to be lower than Q2 due to a more difficult year-over-year comparison and the absence of large GMP protein orders that contributed to Q2 growth.
TECH FAQs
How does TECH typically perform around its earnings report dates?
Is Bio-Techne Corp (TECH) Q2 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TECH Earning Call Sentiment
Earnings call transcript: Bio-Techne beats Q2 2024 forecasts, stock surges
TECH.O
3.81%Positive
The earnings call summary and Q&A highlight several positive aspects: a 9% YoY revenue increase, improved gross margins, and strong shareholder returns through dividends and buybacks. Despite competitive pressures and FX impact, the company shows resilience with growth in key segments and strategic focus on M&A. The Q&A reveals optimism in AI and multi-omic capabilities, though management's reluctance to provide specific guidance on GMP reagents is a slight concern. Overall, the financial performance and strategic initiatives suggest a positive stock price movement.
